Protagonist Therapeutics, Inc Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Protagonist Therapeutics, Inc (PTGX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $51.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-25
- Protagonist Therapeutics, Inc valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $51.70M.
- Protagonist Therapeutics, Inc valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was -$50.90M, a 281.14% decline from fiscal 2023.
- Protagonist Therapeutics, Inc valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $28.10M, a 17.84% decline from fiscal 2022.
- Protagonist Therapeutics, Inc valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $34.20M, a 6.88% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $51.70M 10-K · filed 2026-02-25 | |
| 2024-12-31 | -$50.90M 10-K · filed 2026-02-25 | $50.90M 10-K · filed 2025-02-21 |
| 2023-12-31 | $28.10M 10-K · filed 2026-02-25 | |
| 2022-12-31 | $34.20M 10-K · filed 2025-02-21 | |
| 2021-12-31 | $32.00M 10-K · filed 2024-02-27 | |
| 2020-12-31 | $19.40M 10-K · filed 2023-03-15 | |
| 2019-12-31 | $18.50M 10-K · filed 2022-02-28 | |
| 2018-12-31 | $8.20M 10-K · filed 2021-03-10 | |
| 2017-12-31 | $1.90M 10-K · filed 2020-03-10 | |
| 2016-12-31 | $13.40M 10-K · filed 2019-03-12 | |
| 2015-12-31 | $3.00M 10-K · filed 2018-03-07 | |
| 2014-12-31 | $2.90M 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |